CD274 and non-small cell lung carcinoma: Pembrolizumab is a first-line treatment for Non-Small-Cell Lung Cancer (NSCLC) with PD-L1 expression of 50% or higher and is approved for gastric cancer with a Combined Positive Score (CPS) of 1 or higher.